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 This project focused on the development of amphiphiles in order to prevent 
hospital-acquired infections before they have a chance to enter the host, thereby reducing 
the need for antibiotics. The antibiotic resistance crisis of the 21st century is a dangerous 
epidemic with global consequences. Therefore, there is a desperate need for novel 
approaches in antimicrobial research. This would decrease the overall length of stay in 
hospitals and costs associated with such a stay. In this study, tetracationic amphiphiles 
with two 12-carbon chains and an aliphatic linker were studied. The MIC value of each 
amphiphile and strain pair was determined and compared. Linker length, the distance 
between head groups attached to identical hydrophobic tails appears to affect 
antimicrobial activity. Amphiphiles with longer linkers tend to be more potent 
antibacterial agents than those with shorter linkers. Amphiphiles were also used in 
combination with antibiotics to determine whether the combinations interacted 
synergistically to kill bacteria. The most potent amphiphile was 12-B-10-B-12 against all 
bacteria. This amphiphile was longer in linker length relative to other derivatives, 
suggesting that there is a relationship between linker length and antimicrobial potency. 
The development of novel amphiphiles may be one way to reduce the need for antibiotics 













 In 2013, the CDC reported more than two million Americans are infected with an 
antibiotic-resistant bacterial infection each year, contributing to more than 23,000 deaths 
in the U.S. per year (CDC, 2013)These infections span a diverse list of illnesses including 
skin and surgical site infections, urinary tract infections, pneumonia, bacteremia, and 
hospital-associated diarrhea. Approximately 2 million patients contract a healthcare-
acquired infection each year (Klevens et al., 2007) at a cost of  $28 - $33 billion in 
healthcare annually (Scott, 2009). The cost of antibiotic-resistant infections to a single 
hospital has been estimated to be as high as $13.35 million a year (Scott, 2009).  In the 
past 15 years, only four novel antimicrobial classes have been approved for clinical use. 
Resistance to these agents has already been observed in enterococci and staphylococci 
(Klevens et al., 2007). Infections from antibiotic resistant bacteria have become more 
prevalent in the 20th century. There are growing challenges in treating these infections; 
therefore clinicians must work to limit the transmission of bacteria between contaminated 
equipment and/or staff to susceptible individuals. This is critical for preventing 
nosocomial infections and reducing mortality rates. 
When the introduction of antibiotics, antiseptics, and disinfectants came into 
existence, public health was forever modified. These compounds were able to improve 
sanitation methods and reduce the spread of infectious diseases, most specifically in 
health care settings (Sköld, 2006). Communicable diseases, such as tuberculosis, 
pneumonia, and diarrhea, once ranked as top killers globally, now have been replaced by 
many chronic conditions due to the use of antimicrobials (Kochanek et al., 2011). 
        Although this generation has seen many benefits from the use of antimicrobials in 
	 7	
controlling these infections, hospital-acquired infections (HAI) have posed a major threat 
to patients receiving health care. These infectious agents are dangerously gaining 
resistance to commonly used antimicrobials. HAIs frequently lead to increasing medical 
costs, longer hospital stays, increasing complication rates, and worsening overall 
morbidity and mortality (Klevens et al., 2007). Many countries and hospitals have 
adopted policies and regulations in recent years attempting to decrease the impact of 
these healthcare-associated infections. Not only would reducing HAIs be beneficial to the 
patients themselves, it would also be highly beneficial to healthcare centers and insurance 
companies (Scott, 2009). 
An increasing proportion of HAIs are resistant to various antibiotics. The rate of 
Staphylococcus  aureus strains found in hospitals that were methicillin-resistant is 
increasing. MRSA, methicillin resistant Staphylococcus aureus, was once detected at a 
rate of 1-5% in the 1980’s to 60-70% in recent years, proving greater incidence (Taubes, 
2008). Multi-drug resistant Pseudomonas aeruginosa has become relatively common in 
Intensive Care Units (ICUs), accounting for 13.2% to 22.6% of HAIs reported in this 
environment (Driscoll et al., 2007). Bacterial drug-resistance forces healthcare providers 
to resort to more expensive and potentially more harmful therapies (McGowan, 2001; 
Cosgrove & Carmeli, 2003). Patients with infections that are resistant to all available 
antibiotics often have to undergo surgical removal of the infection, which may include 
amputations (Cosgrove & Carmeli, 2003). 
 The rapid emergence of resistant bacteria has diminished the efficacy of 
antibiotics. The antimicrobial resistance of many pathogenic bacteria can be attributed to 
the regular overuse and misuse of antibiotics (Ventola, 2015). Unfortunately, resistance 
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has been documented for almost all antibiotics developed. Despite the known danger of 
antibiotic resistance, antibiotics are continually misused, over-prescribed, and abused in a 
number of industries including agriculture. Industrial use has contributed greatly to the 
vast increase in antibiotic resistance, particularly in human pathogens such as methicillin-
resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), and multi-drug 
resistant P. aeruginosa and Mycobacterium tuberculosis (MDR-TB) (Gilbert & Moore, 
2005). This increase has diminished the effectiveness of first- and second-line therapies 
for infectious disease, extending illness, and increasing the risk of mortality (Taubes, 
2008). 
         Proper hygienic practices, including hand washing, are the easiest, most effective 
and cost efficient ways to prevent HAIs (Braine et al, 2009). Reducing surface 
contamination is one way that infections can be combated. Surface contamination can be 
extremely problematic when contaminated surfaces come in contact with a patient’s open 
wound or surgical equipment, catheters, or ventilators used on a patient (Weber et al., 
2010). This potential contamination has increasingly negative effects on patients in 
hospitals, particularly those with compromised immune systems. Reducing potential 
cross contaminations between health care professionals and patients, whether it be by 
contact between persons or contact with hospital equipment prevents pathogen reservoirs 
from forming and reduces the risk of infection for patients. The need for novel 
antimicrobials is extremely important during this time of antibiotic resistance.  
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Cationic amphiphiles, compounds with at least one hydrophilic head group and 
hydrophobic tail (Figure 1), can have antibacterial properties. It is generally thought that 
amphiphiles work by targeting the cell membranes of bacteria. The amphiphile’s 
positively charged head group interacts electrostatically with the negatively charged cell 
membrane of the bacterium, allowing hydrophobic tails to insert into the membrane and 
disrupt or destabilize it. When the membrane is disrupted, cytoplasmic materials leak out 
and cell lysis occurs. (Gilbert & Moore, 2005). Amphiphiles have served as antimicrobial 
agents in many industries. For example, benzalkonium chloride and chlorhexidine are 
active ingredients in topical antiseptics such as Neosporin®, mouthwash, and common 
disinfecting products, including Lysol® (Gilbert & Moore, 2005). These compounds 
have been successful for many decades and bacteria have no documented resistance to 
them (Gilbert & Moore, 2005). Therefore, there is great potential for cationic 
amphiphiles as antimicrobials. 
 
 Gemini amphiphiles, which contain four cationic head groups with two attached 
12-carbon tails and a linkage group (Figure 2), are the main focus of this research 
because of their proven potent antimicrobial activity against Gram-negative and Gram-
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positive bacteria. Dialkyl 4,4’- bipyridium amphiphiles with 12 carbon tails have been 
recognized as a potentially efficient group of membrane disruptors (Grenier et al. 2012). 
Dialkyl 4,4-bipyridium compounds, which include a gemini (two heads, two tails) 
structure (Figure 2), are effective against highly resistant bacterial strains such as E. coli 
and P.aeruginosa  (Grenier et al. 2012). The compounds specifically used in this study 
all possess a 12-carbon tail.  What is unique about each compound is the linker length 
varying from 6-12-carbons in length (Figure 2). Each of these amphiphiles possesses a 
tetracationic structure, with four head groups that possess a total of 4 positive charges.  
Figure 2. Dialkyl 4,4’-bipyridium amphiphiles. 
 There is much interest in developing single antimicrobials or combinations of 
drugs that have activity against multiple microorganisms (Giacometti et al, 2000. 
Tobramycin is an aminoglycoside antibiotic that is used to treat various types 
of bacterial infections, particularly Gram-negative infections. It is especially effective 
against species of Pseudomonas. Oxacillin is a penicillinase-resistant antibiotic that is 
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widely used clinically in the United States to treat penicillin-resistant bacterial infections, 
such as ones caused by S. aureus (Jones et al, 2002). In this study, novel amphiphiles 
were used in combination with different antibiotics, tobramycin and oxacillin, to 
determine if the combinations interacted synergistically to kill bacteria. 
The antibacterial activity of a series of 4,4’-bipyridinium compounds against Gram- 
positive and Gram-negative pathogens was investigated to further analyze the effects of 
various structural features on antibacterial activity. In this study, antimicrobial properties 
of novel amphiphiles were explored by determining MIC values. These MIC values were 
determined and analyzed in order to determine the relationship between linker length and 
antimicrobial activity of amphiphiles. Amphiphile 12-B-10-B-12 was a potent killer 
against all Gram-positive and Gram-negative bacteria.  
 Combination assays were then performed in order to detect possible synergistic 
relationships between other novel amphiphiles and tobramycin and oxacillin. Although 
no significant results were obtained with these specific combinations, preliminary 















Materials and Methods 
Bacterial Strains and Growth Conditions 
 
The Gram-negative bacterial strains used in this study were Escherichia coli 
ATCC® 25922™, Klebsiella pneumoniae, Pseudomonas aeruginosa ATCC® 27853™ 
for experiments with planktonic cells, and hyper-biofilm forming strain PAO2 for biofilm 
disruption studies (Holloway, 1955).  The Gram-positive bacterial strains used were 
Staphylococcus aureus subsp. aureus ATCC 29213™, Enterococcus faecalis ATCC® 
29212™, Bacillus anthracis Sterne, Streptococcus agalactiae J48 (Seifert et al., 
2006).  All bacterial strains, except for PAO2 were grown in MHB.  For biofilm studies, 
PAO2 was grown in Luria-Bertani (LB) broth. 
 
Broth Microdilution Method for Determining the Minimum Inhibitory Concentration 
 
Students from James Madison University under the direction of Dr. Kevin Caran 
synthesized the amphiphiles in this study. The Minimum Inhibitory Concentration (MIC) 
was determined for each amphiphile against four Gram-positive and three Gram-negative 
bacterial strains as previously described (CLSI, 2012). The MIC was determined using 
the broth microdilution method (Wayne, 2009). Bacterial cultures were grown overnight 
at 37°C and diluted in MHB to a concentration of 5x106 cells/mL. Aliquots of 100µL of 
bacteria were added to 96-wells plates along with 100µL of amphiphile being tested at 2-
fold dilutions, from 500µM to 2µM, in triplicate. The plates were incubated at 37°C for 
72 hours. The wells with the lowest concentration of amphiphile without visible growth 





A checkerboard assay using 96-well microtiter plates was used to determine if 
synergy exists when amphiphiles are combined with other compounds against E.coli 
ATCC® 25922™ and S. aureus ATCC® 29213™ (ATCC, Manassas, VA, 
USA).  Bacteria diluted to 5x106 cell/mL was added to each well yielding 5x105 cell/mL 
in each well.  Wells with sterile deionized H2O treatment were used as a control for 
bacterial growth.  In the checkerboard section of the assay, 50µl of each compound at 2-
fold dilutions at concentrations below the previously determined MIC of each compound 
was added to individual wells, such that multiple combinations of the two compounds are 
tested on a single plate. The Fractional Inhibitory Concentration (FIC) was determined by 
comparing the MIC value of each compound alone and in combination using the 
following equation:  
FIC = FICA + FICB 
FICA = A/MICA 
FICB = B/MICB 
MICA and MICB represent the MIC of compound A and B alone and A and B represent 
the MIC values of compound A and compound B combined.  Synergy was defined as an 
FIC value of <0.5, and antagonism was defined as an FIC value of  >4.  Synergy assays 











Effect of Varying Linker Length of Gemini Bipyridium Amphiphiles on antibacterial activity 
To determine the effect of varying linker length on antimicrobial activity, MIC 
assays were performed with dialkyl 4,4’-bipyridium amphiphiles that had varying linker 
lengths ranging from 6-12 carbons (Table 1, 2). The variation in linker length resulted in 
a trend that as linker length increases, MIC values decrease for species such as Gram-
negative, K. pneumonia (Table 2). As linker length increased, MIC values increased, for 
Gram-positive species such as E. faecalis and S. aureus (Table 1), showing that, in this 
case, shorter linker lengths were more effective. When 4,4’-bipyridium amphiphiles 
treated Gram-positive S. agalactiae and B. anthracis there showed promising results but 
no definitive trends (Table 1). When 4,4’-bipyridium amphiphiles treated Gram-negative 
P. aeruginosa and E.coli again, there showed no definitive trends (Table 2). Overall, the 
most effective amphiphile was 12-B-10-B-12 against all bacteria (Figure 3,4), showing 
that a linker length of 10-carbons was optimal. Amphiphiles were generally more 
effective against Gram-positive bacteria than they were against Gram-negative bacteria.  
B.anthracis appears to be most sensitive to all amphiphiles tested (Figure 3).  
Table 1. Minimal Inhibitory Concentrations (µM) for amphiphiles against Gram-positive 
bacteria. 
n-B-n-B-n E. faecalis S. aureus S. agalactiae B. anthracis 
12-B-6-B-12 8 4 4 2 
12-B-9-B-12 8 8 4 2 
12-B-10-B-12 8 4 1 1 
12-B-11-B-12 16 32 4 1 





Table 2. Minimal Inhibitory Concentrations (µM) for amphiphiles against Gram-negative 
bacteria. 
n-B-n-B-n2 P. aeruginosa E. coli K. pneumoniae 
12-B-6-B-12 32 16 32 
12-B-9-B-12 16 16 16 
12-B-10-B-12 16 8 8 
12-B-11-B-12 8 16 8 












Figure 3. Log [MIC(µM)] values of dialkyl 4’4 bipyridium amphiphiles for Gram-













































































































Effect of Synergy between Cationic Amphiphiles and Antibiotics on E. coli 
Four series of double tailed tris-cationic amphiphiles were synthesized by the 
Caran lab (James Madison University). For each series, the amphiphiles consisted of a 
mesitylene core (M) with three attached positively charged head groups. Two of these 
head groups were dimethylalkylammonium groups with attached hydrocarbon tails. The 
third head group was either ethanolammonium for the M-E,n,n series, 
dimethylaminopyridinium for the M-DMAP,n,n series, isoquinolinium for the M-IQ,n,n 
series, and 4-pyridine propanol for the M-4PP,n,n series. The hydrocarbon tails were 




The tetra-cationic amphiphile series were structured similarly, however two 
dimethylalkylammonium head groups were attached to each of the same positions on the 
central ring, connected by a 2-carbon linker. The linear hydrocarbon tail connected to the 
M-E,n,n series 
n = 12 
M-DMAP,n,n series 
n = 12 
M-IQ,n,n series 
n = 12 
M-4PP,n,n series 
n = 12 
Figure 5. Structure of amphiphiles. M represents the Mesitylene core; n represents the number of 
carbons in each symmetrical hydrocarbon tail. E = ethanolammonium, DMAP = 
dimethylaminopryidinium, IQ = isoquinolinium, and 4PP = 4-pyridine propanol. 	
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head group in each of the tetra-cationic series contained 8 or 10 carbons for the pX-(2,n)2 








Tobramycin and oxacillin are both known to be effective antibiotics and were 
combined with these amphiphiles to determine if they acted synergistically when used on 
E. coli. Based on the FIC values, there was not synergy with any of these combinations 
(Table 3), though it was close in some cases (e.g., PX(2,8)2).  
 
Table 3. FIC values for amphiphile and antibiotic synergy assays. A value of  <0.5 
indicates synergy while a value of  >4 indicates antagonism. “ND” represents “Not Done.” 
 Tobramycin  Oxacillin  
M-E,12,12 0.708 1.09 
M-DMAP,12,12 0.917 0.909 
M-IQ,12,12 0.625 0.704 
M-4PP,12,12 0.664 0.915 
PX(2,8)2 0.501 0.506 









n = 8,10 
Figure 6. Structure of tetra-cationic amphiphiles. n represents the number of carbons in each 
symmetrical hydrocarbon tail.; pX = para-orientation.  
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Discussion 
 Dialkyl 4,4’-bipyridium amphiphiles with linker lengths varying from 6-12 
carbons, were studied to determine if linker length affected MIC values. As linker length 
increased, MIC values increased, for E. faecalis and S. aureus. This type of relationship 
has been described with other amphiphiles as well (Palermo et al, 2012).  
 Since linker length is correlated with activity of the amphiphile, it is reasonable to 
assume that as the linker length increases, the flexibility of the amphiphile increases, thus 
allowing the amphiphile to penetrate the cell membrane of the bacteria more effectively. 
As the head groups attach to the membrane of the bacterial cell, the linkers may help 
drive the amphiphile through the membrane to induce cell lysis of the bacterial 
membrane (Lombardo et al, 2015). 
 The compounds with longer linker lengths were more effective at disrupting the 
Gram-positive membranes, resulting in lower MICs. Gram-negative bacteria are 
generally less penetrable by antimicrobials because they have two lipid bilayer 
membranes with a tightly packed lipid polysaccharide (LPS) layer in the outer membrane 
(Khalil et al., 2008), consistent with generally higher MIC values.  
 Synergy between cationic amphiphiles and antibiotics on E. coli was investigated. 
Although there was not synergy with any of these combinations, synergy has been 
observed with other compounds of similar structure. Other studies have indicated that 
amphiphiles can increase effectiveness of antibiotics (Purdy et al, 2009), and will be 
investigated further.  
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 There are several avenues of investigation that could broaden this study. First, 
studies on increased linker length would be reasonable. Combination therapies were 
explored in this study, but further investigation should be done because synergy between 
amphiphiles and antibiotics has been documented (Purdy et al, 2009). The rate of killing 
of these amphiphiles is also worth further research because developing a potent 
amphiphile that works quickly would be preferable for product development. Such 
endeavors would help expand the understanding of structural features that optimize the 
antibacterial activity of dialkyl 4,4’-bipyridium amphiphiles.  
 When developing antimicrobials for disinfectant purposes, it is very important to 
consider the factors that affect resistance in order to combat healthcare-acquired 
infections. It is important that the antibacterial agent does not harm eukaryotic cells. A 
parallel avenue to study would be to determine the toxicity of these amphiphiles on 
eukaryotic cells. Ideally, a disinfectant would selectively target bacterial membranes, 
which would be of great interests to hospitals in preventing healthcare-acquired 
infections. Medical professionals must stop over-prescribing antibiotics that are 
ineffective against bacteria and embrace effective antiseptics and disinfectants such as 
amphiphiles. While bacteria are becoming increasing resistant to commercially available 
antimicrobials, research is moving towards novel approaches to combat antibiotic 
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